Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PXL770 is a novel, firstin-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. PXL065 is a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone which exerts effects via multiple non-genomic pathways engaged by thiazolidinedione.
Lead Product(s): PXL770
Therapeutic Area: Genetic Disease Product Name: PXL770
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
PXL065 is a novel, proprietary deuterium-stabilized R-pioglitazone. PXL065 was observed to be safe and well tolerated with no dose-dependent increase in body weight and no increased lower extremity edema vs. placebo.
Lead Product(s): Deuterium Stabilized (R)‐Pioglitazone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PXL065
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
PXL770 is a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. AMPK is a central regulator of multiple metabolic pathways leading to the control of lipid metabolism, glucose homeostasis and inflammation.
Lead Product(s): PXL770
Therapeutic Area: Genetic Disease Product Name: PXL770
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
PXL065 (deuterated pioglitazone) Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses.
Lead Product(s): Deuterium Stabilized (R)‐Pioglitazone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PXL065
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022
Details:
PXL065 is a novel, proprietary deuteriumstabilized R-stereoisomer of pioglitazone which exerts effects via multiple non-genomic pathways engaged by thiazolidinedione molecules.
Lead Product(s): Deuterated Pioglitazone
Therapeutic Area: Genetic Disease Product Name: PXL065
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
PXL065 is the deuterated-stabilized R stereoisomer (single R-isomer) of pioglitazone, its parent molecule. It is currently being evaluated in a Phase 2 study (DESTINY-1) for NASH, with results expected in Q3 2022.
Lead Product(s): Deuterated Pioglitazone
Therapeutic Area: Genetic Disease Product Name: PXL065
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
PXL065 (deuterium-stabilized R-pioglitazone) was observed to ameliorate key features of ALD in preclinical models, including both patient-derived cells and a classical rodent disease model.
Lead Product(s): Deuterated Pioglitazone
Therapeutic Area: Genetic Disease Product Name: PXL065
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
The results showed that treatment with PXL770 at 500 mg QD resulted in significant reductions in mean liver fat content and alanine transaminase (ALT) levels (vs. baseline).
Lead Product(s): PXL770
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PXL770
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Details:
The companies entered into a strategic partnership for the development and commercialization of Twymeeg (imeglimin hydrochloride) in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.
Lead Product(s): Imeglimin Hydrochloride
Therapeutic Area: Endocrinology Product Name: Twymeeg
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sumitomo Pharma
Deal Size: $299.0 million Upfront Cash: $42.0 million
Deal Type: Partnership June 23, 2021
Details:
Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program.
Lead Product(s): Imeglimin Hydrochloride
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Metavant Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Terminated January 14, 2021